Two distinct clinical patterns of ibrutinib-to-venetoclax transition in relapsed chronic lymphocytic leukemia patients
I Ferrarini, F Gandini, E Zapparoli, A Rigo - Current Oncology, 2022 - mdpi.com
Patients with chronic lymphocytic leukemia (CLL) relapsing on ibrutinib are often treated
with the Bcl-2 inhibitor venetoclax. However, the transition from one agent to another poses …
with the Bcl-2 inhibitor venetoclax. However, the transition from one agent to another poses …